Ensign Peak Advisors, Inc Kodiak Sciences Inc. Transaction History

Ensign Peak Advisors, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.57 - $12.5 $28,387 - $46,875	3,750 Added 64.43%	9,570 $74,000
Q4 2021 Feb 11, 2022	BUY	$80.85 - $128.49 $470,546 - $747,811	5,820 New	5,820 $493,000
Q3 2021 Nov 12, 2021	SELL	$81.97 - $106.94 $81,970 - $106,940	-1,000 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$77.2 - $126.54 $77,200 - $126,540	1,000 New	1,000 $93,000
Q1 2021 May 12, 2021	SELL	$110.45 - $164.47 $2.52 Million - $3.75 Million	-22,807 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$60.78 - $154.03 $123,869 - $313,913	2,038 Added 9.81%	22,807 $3.35 Million
Q3 2020 Nov 12, 2020	BUY	$45.05 - $59.27 $858,517 - $1.13 Million	19,057 Added 1113.14%	20,769 $1.23 Million
Q1 2020 May 11, 2020	BUY	$38.18 - $73.95 $65,364 - $126,602	1,712 New	1,712 $82,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.